Results 191 to 200 of about 12,269 (257)

Should TNF inhibitors be avoided in psoriasis patients with latent tuberculosis?

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Fabià Torres‐Betato, Lluís Puig
wiley   +1 more source

International consensus on dose reduction of biologics for patients with psoriasis: The DR. Delphi study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Dermatologists worldwide reached consensus on criteria for dose reduction (DR) of biologics for psoriasis resulting in a DR algorithm for adalimumab, etanercept and ustekinumab. DR of IL‐17 and IL‐23 inhibitors was deemed feasible as well. This first international consensus provides essential information for uptake of biologic DR for psoriasis globally.
C. A. M. van Riel, W.‐H. Boehncke, J. L. W. Lambert, P. I. Spuls, L. S. van der Schoot, I. van Ee, E. M. G. J. de Jong, J. M. P. A. van den Reek, on behalf of the eDelphi consortium, M. Elkalioby, L. Fianen, L. Linhares Leite, C. Boesjes, S. Mahil, M. Franco, F. Valenzuela, C. Chaiyabutr, M. A. Lorna, F. Frez, O. Zargari, T. Hillary, H. Oon, L. Skov, M. Gupta, E. Sotiriou, N. Nguyen Loft, R. Ceovic, K. M. G. Klaassen, J. Wikström, C. Zachariae, P. Asawanonda, R. Vender, A. Carvalho, J. Song, C. Lan, J.‐T. Maul, D. Jullien, B. Hidalgo‐Matlock, A. Duvetorp, M. Gkini, D. Ioannidis, W. Veldkamp, J. Hugo, J. Barboza, A. Carugno, A. Londoño‐García, L. Schneller‐Pavelescu Apetrei, M. Ferran, F. Lafuente Urrez, N. Merino, M. Llamas Velasco, L. Puig, M. Bourcier, M. Perez Ferriols, T. Leonidze, D. Armijo, A. Eylenbosch, M. B. A. van Doorn, P. P. M. van Lumig, P. Ghislain, A. Nast, S. Lanssens, E. Sonkoly, D. J. Hijnen, E. M. Baerveldt, P. Gisondi, M. Tjioe, I. Haeck, K. Agerberg, Y. Okubo   +69 more
wiley   +1 more source

Photoprotective practices in patients with mycosis fungoides: a questionnaire‐based survey study

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Ioannis‐Alexios Koumprentziotis, Antonis Tsimpidakis, Maria Gerochristou, Stella Kaliampou, Eleni Tsefou, Alexander Stratigos, Vasiliki Nikolaou   +6 more
wiley   +1 more source

Durability of response to icotrokinra for high‐impact site psoriasis: 1‐year ICONIC‐TOTAL findings

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Participants with at least moderate scalp, genital or hand/foot psoriasis receiving once‐daily oral icotrokinra achieved high, durable rates of overall and high‐impact site psoriasis clearance, showed substantial nail psoriasis improvement and exhibited no safety signals through 1 year, supporting icotrokinra use for long‐term management of high‐impact
Richard B. Warren, Melinda Gooderham, Edward Lain, Robert Bissonnette, Yu‐Huei Huang, Julien Ringuet, Matthias Hoffmann, Andreas Pinter, Joseph F. Merola, Jessica H. Rubens, Dorothy Fan, Ming‐Chun Hsu, Shu Li, Ya‐Wen Yang, Cynthia M. C. DeKlotz, Eingun James Song   +15 more
wiley   +1 more source

High‐Concentration Hydrogen Peroxide Gels Containing Calcium Polyphosphate Associated With Violet Led Light: Bleaching Efficacy and Effects on Enamel Properties

Journal of Esthetic and Restorative Dentistry, EarlyView.
ABSTRACT Objectives To evaluate the effect of violet LED light (VL) and hydrogen peroxide (HP) in‐office bleaching gels supplemented with calcium polyphosphate (CaPP) or calcium gluconate (GU): Materials and Methods Bovine enamel blocks (n = 10) were randomly assigned: commercial HP gel, commercial HP gel with GU, or experimental 35% HP with or without
Hemanuelly Albuquerque dos Anjos, Débora Alves Nunes Leite Lima, Carolina Meneghin Barbosa, Klaus Rischka, Waldemir Francisco Vieira‐Junior   +4 more
wiley   +1 more source

Oral Microbiome in Systemic Autoimmune Diseases: A Systematic Review

Oral Diseases, EarlyView.
ABSTRACT Objective The oral cavity represents a key but underexplored interface between host immunity and microbial communities. The aim of this systematic review was to synthesize current literature on oral microbiota alterations in systemic autoimmune diseases.
Sophie Jung, Eirini Militsi, Olivier Huck   +2 more
wiley   +1 more source

Novel Combination of UVA‐1 Phototherapy With Topical Tofacitinib for Treating Eosinophilic Fasciitis With Morphea: Case Report

Pediatric Dermatology, EarlyView.
ABSTRACT Eosinophilic fasciitis (EF) and morphea are rare sclerosing connective tissue disorders, and there remains debate about whether these entities are pathologically distinct or related. This case report describes the successful treatment of an adolescent patient who developed progressive morphea plaques while being treated with systemic ...
Daphne M. Cheung, Ye‐Jean Park, Nadia Luca, Frankie Fraulin, Marie‐Anne Brundler, Michele Ramien   +5 more
wiley   +1 more source

Dupilumab‐Induced Psoriasis in an Adolescent With Severe Atopic Dermatitis: Successful Management With Abrocitinib

Pediatric Dermatology, EarlyView.
ABSTRACT Psoriasiform eruptions have been described in patients treated with dupilumab. This case report describes an adolescent with severe atopic dermatitis who developed a widespread psoriasiform dermatitis 8 months after starting dupilumab. His therapy was switched to abrocitinib resulting in near‐complete resolution of the psoriatic lesions with ...
Grigorios Theodosiou, Åke Svensson
wiley   +1 more source

Safety of Dupilumab and Risk of Cutaneous T‐Cell Lymphoma in Pediatric Patients With Atopic Dermatitis: A Data‐Driven Guide to Counseling Patients and Families

Pediatric Dermatology, EarlyView.
ABSTRACT Recent publications reporting increased cutaneous T‐cell lymphoma (CTCL) risk with dupilumab in atopic dermatitis (AD) have sparked debate, amplified by media coverage linking dupilumab to lymphoma. These concerns have reached pediatric populations, where we observe increasing parental hesitancy about initiating dupilumab for their children ...
Maria Gnarra Buethe, Tyler Sy, Lawrence F. Eichenfield   +2 more
wiley   +1 more source

PHOTOTHERAPY IN ERYSIPELAS [PDF]

BMJ, 1932
openaire   +2 more sources